Stibbe advises a leading pharmaceutical company

Stibbe advises a leading pharmaceutical company

10.04.2013 BE law

Assisting our client in identifying the most cost-effective way to obtain in Belgium an improved pricing and reimbursement for new fixed-dose combination products composed of off-patent ingredient and for combination products that are registered based on a well-established use.

The strategy we developed for the client consists of mixing the various types of product registration to influence pricing/reimbursement. It is essential for our client to differentiate its products from those of its competitors so that it could mitigate the impact of price cuts imposed by the authorities.


Related experience

Our website uses cookies: third party analytics cookies to best adapt our website to your needs & cookies to enable social media functionalities. For more information on the use of cookies, please check our Privacy and Cookie Policy. Please note that you can change your cookie opt-ins at any time via your browser settings.

Privacy and Cookie Policy